Physician profile
Navin Anthony
NPI 1174645287
$2,461.89
in general payments reported to CMS, 2019-2025
37 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $577 · 2021: $118 · 2022: $388 · 2023: $125 · 2024: $125 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.74 |
| Education | $181.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Astellas Pharma US INC | $173.74 | 2020-2023 | Padcev |
| Amgen INC. | $166.95 | 2019-2022 | |
| Beone Medicines USA, INC. | $145.41 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $143.68 | 2021-2024 | Ojjaara |
| Pfizer INC. | $139.63 | 2019-2022 | |
| Seagen INC. | $111.78 | 2019-2025 | |
| Genentech USA, INC. | $104.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $98.95 | 2019-2022 | |
| Genzyme Corporation | $96.40 | 2019-2022 | |
| Novocure INC. | $92.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $92.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $81.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.44 | 2019-2020 | |
| Celgene Corporation | $51.81 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $50.92 | 2019-2022 | |
| Janssen Biotech, INC. | $48.79 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $43.81 | 2019-2022 | |
| Dova Pharmaceuticals | $37.35 | 2019 | |
| Incyte Corporation | $36.50 | 2019-2022 | |
| Tactile Systems Technology INC | $33.39 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $32.98 | 2019-2023 | Libtayo |
| Lilly USA, LLC | $29.49 | 2019 | |
| Kite Pharma, INC. | $28.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.55 | 2019 | |
| Beigene USA, INC. | $21.05 | 2022 | |
| Tesaro, INC. | $19.69 | 2019 | |
| Taiho Oncology, INC. | $19.52 | 2019 | |
| Abbvie INC. | $17.48 | 2019 | |
| Emd Serono, INC. | $16.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.18 | 2022 | |
| Exelixis INC. | $16.02 | 2019 | |
| Partner Therapeutics, INC. | $14.47 | 2020 | |
| Cardinal Health 414 LLC | $13.79 | 2019 | |
| Puma Biotechnology, INC. | $12.81 | 2021 | |
| Convatec INC. | $12.15 | 2019 | |
| Array Biopharma INC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.